Antibody-Drug Conjugates SOT109

SOTIO is developing SOT109 for solid tumors as an ADC against an undisclosed target. SOT109 utilizes Synaffix’s proprietary GlycoConnectTM HydraSpace™ clinical-stage conjugation platform. Synaffix’s conjugation technology, which replaces the existing antibody glycan with a therapeutic payload, combined with optimized linker, enables wide therapeutic efficacy and tolerability (learn more here).